Abstract
Investigation of the mechanisms of atherosclerosis has determined that inflammation plays a central role in the development, progression, and outcome of acute coronary syndrome (ACS). C-reactive protein (CRP) plasma levels increase in patients with ACS. CPR is an important prognostic marker in ACS, following angioplasty, and in the long-term management of post-infarction patients. Although CRP will remain over time a useful marker, the role and implications of increased plasma concentrations of other acute phase proteins (APPs), such as alpha-1-antitrypsin (A1AT), alpha-1 glycoprotein (A1GP), haptoglobin (HG), ceruloplasmin (CP), and C3c and C4 complement fraction, in patients with ACS are still not completely defined. This short review summarizes the experimental and clinical evidence regarding the role, and the biological and clinical significance of these other APPs in ACS.
Keywords: Acute phase proteins, acute phase reactants, inflammation-sensitive plasma proteins, acute coronary syndrome, atherosclerosis, acute myocardial infarction
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
Volume: 6 Issue: 4
Author(s): Michele Correale, Natale Daniele Brunetti, Luisa De Gennaro and Matteo Di Biase
Affiliation:
Keywords: Acute phase proteins, acute phase reactants, inflammation-sensitive plasma proteins, acute coronary syndrome, atherosclerosis, acute myocardial infarction
Abstract: Investigation of the mechanisms of atherosclerosis has determined that inflammation plays a central role in the development, progression, and outcome of acute coronary syndrome (ACS). C-reactive protein (CRP) plasma levels increase in patients with ACS. CPR is an important prognostic marker in ACS, following angioplasty, and in the long-term management of post-infarction patients. Although CRP will remain over time a useful marker, the role and implications of increased plasma concentrations of other acute phase proteins (APPs), such as alpha-1-antitrypsin (A1AT), alpha-1 glycoprotein (A1GP), haptoglobin (HG), ceruloplasmin (CP), and C3c and C4 complement fraction, in patients with ACS are still not completely defined. This short review summarizes the experimental and clinical evidence regarding the role, and the biological and clinical significance of these other APPs in ACS.
Export Options
About this article
Cite this article as:
Correale Michele, Brunetti Daniele Natale, De Gennaro Luisa and Biase Di Matteo, Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome), Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6(4) . https://dx.doi.org/10.2174/187152508785909537
DOI https://dx.doi.org/10.2174/187152508785909537 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?
Current Bioactive Compounds Physical Activity and Hypertension: Evidence of Cross-Sectional Studies,Cohort Studies and Meta-Analysis
Current Hypertension Reviews PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Editorial [Hot Topic: Cardiovascular and Hematological Agents (Executive Editor: Johann Auer)]
Current Pharmaceutical Design Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry ATP-Sensitive K+ Channel Openers: Old Drugs with New Clinical Benefits for the Heart
Current Vascular Pharmacology Triggers and Anatomical Substrates in the Genesis and Perpetuation of Atrial Fibrillation
Current Cardiology Reviews Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Current Medicinal Chemistry Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists
Current Drug Targets How to Measure Exercise Performance
Current Respiratory Medicine Reviews The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target
Current Pharmaceutical Design